Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5171496 | 0.98 | ALDH1A1 (0.56) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1726778 | 0.98 | ALDH1A1 (0.56) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4881400 | 0.96 | ALDH1A1 (0.55) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL27467629 | 0.89 | ALDH1A1 (0.58) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL8580399 | 0.87 | ALDH1A1 (0.56) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL7483779 | 0.87 | ALDH1A1 (0.56) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL5326822 | 0.86 | ALDH1A1 (0.51) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL21782232 | 0.86 | ALDH1A1 (0.55) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL8694065 | 0.86 | ALDH1A1 (0.55) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 | |
| SCHEMBL28010869 | 0.86 | ALDH1A1 (0.55) | ALDH1A1KMT2ATDP1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125423-A1 | PEPTIDES FOR INCRETIN SYNTHESIS | LILLY CO ELI (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4598938-A2 | PEPTIDES FOR INCRETIN SYNTHESIS | Eli Lilly and Company (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250034201-A1 | PRODRUGS OF GANAXOLONE | IMMEDICA PHARMA US INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4493574-A1 | PRODRUGS OF GANAXOLONE | Marinus Pharmaceuticals, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2024130161-A2 | NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | BIONECURE THERAPEUTICS INC (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | NEW YORK UNIVERSITY | 2024-04-18 | — | — | US | disclosed |
| WO-2024077149-A2 | PEPTIDES FOR INCRETIN SYNTHESIS | ELI LILLY AND COMPANY (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| WO-2023178299-A1 | PRODRUGS OF GANAXOLONE | MARINUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-0743857-A4 | METHOD OF MAKING POLYMERS HAVING SPECIFIC PROPERTIES | ARQULE INC (US) | 1998-07-15 | — | — | EP | disclosed |
| EP-0833821-A1 | 1,3-OXAZIN-4-ONE DERIVATIVES AS HERBICIDES | RHONE-POULENC AGRICULTURE LTD. (GB) | 1998-04-08 | — | — | EP | disclosed |
| US-5670480-A | BINDING MODULE UNITS TO EACH OTHER | ARQULE, INC. (US) | 1997-09-23 | — | — | US | disclosed |
| WO-1997032860-A1 | BENZODIAZONINE DERIVATIVES BINDING TO CHOLECYSTOKININ OR GASTRIN RECEPTORS | JAMES BLACK FOUNDATION LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997000865-A1 | 1,3-OXAZIN-4-ONE DERIVATIVES AS HERBICIDES | RHONE-POULENC AGRICULTURE LTD. (GB) | 1997-01-09 | — | — | WO | disclosed |
| EP-0743857-A1 | METHOD OF MAKING POLYMERS HAVING SPECIFIC PROPERTIES | ARQULE, INC. (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995018627-A1 | METHOD OF MAKING POLYMERS HAVING SPECIFIC PROPERTIES | ARQULE, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| EP-0117429-B1 | PHOSPHOROUS CONTAINING COMPOUNDS AS INHIBITORS OF ENKEPHALINASES | SCHERING CORPORATION (US) | 1987-09-02 | — | — | EP | disclosed |
| US-4048306-A | ANTIBACTERIAL | BOEHRINGER INGELHEIM GMBH (DT) | 1977-09-13 | — | — | US | disclosed |
| US-4028319-A | 2 AND 3-SUBSTITUTED ENKEPHALINS | G. D. SEARLE & CO. (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | ALDH1A1 585/4885KMT2A 3433/4885TDP1 2768/4885 |
| US-20250034201-A1 | PRODRUGS OF GANAXOLONE | CYP21A2, CYP11B1, CYP11B2 | ALDH1A1 1430/4885KMT2A 3605/4885TDP1 468/4885 |
| US-20240124539-A1 | CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME | SOS2, SOS1, F2 | ALDH1A1 3199/4885KMT2A 4401/4885TDP1 2410/4885 |
| US-20260125423-A1 | PEPTIDES FOR INCRETIN SYNTHESIS | IAPP, GLP1R, VIP | ALDH1A1 4854/4885KMT2A 3022/4885TDP1 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.